drugset
drugset / Trial / NCT00436995

Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis

NCT00436995 ↗

Phase 3 Completed 114 enrolled Amgen
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the proportion of subjects sucessfully achieving a mean Hemoglobin greater than or equal to 11 g/dL during the evaluation period following extension from Weekly (QW) to Once Every Other Week (Q2W) Darbepoetin Alfa administraion.

Timeline

Start
2006-04
Primary completion
2007-01
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Darbepoetin alfa Protein / enzyme biologic 10 ug Intravenous
Subject Darbepoetin alfa Protein / enzyme biologic 15 ug Intravenous
Subject Darbepoetin alfa Protein / enzyme biologic 20 ug Intravenous
Subject Darbepoetin alfa Protein / enzyme biologic 30 ug Intravenous
Subject Darbepoetin alfa Protein / enzyme biologic 40 ug Intravenous
Subject Darbepoetin alfa Protein / enzyme biologic 50 ug Intravenous
Subject Darbepoetin alfa Protein / enzyme biologic 60 ug Intravenous
Subject Darbepoetin alfa Protein / enzyme biologic 80 ug Intravenous
Subject Darbepoetin alfa Protein / enzyme biologic 100 ug Intravenous
Subject Darbepoetin alfa Protein / enzyme biologic 130 ug Intravenous
Subject Darbepoetin alfa Protein / enzyme biologic 150 ug Intravenous
Subject Darbepoetin alfa Protein / enzyme biologic 200 ug Intravenous
Subject Darbepoetin alfa Protein / enzyme biologic 300 ug Intravenous

Indications

chronic kidney disease